SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3p
Author:
Funder
National Natural Science Foundation of China
Publisher
Elsevier BV
Subject
Pharmacology,General Medicine
Reference37 articles.
1. Cancer Statistics, 2017;Siegel;CA Cancer J. Clin.,2017
2. Non-small cell lung cancer, J. Natl;Ettinger;J. Compr. Canc. Netw.,2010
3. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer;Asami;World J. Clin. Oncol.,2014
4. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung Cancer;Gainor;J. Clin. Oncol.,2013
5. Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer;Wu;Mol. Cancer,2018
Cited by 41 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. lncRNAs: New players of cancer drug resistance via targeting ABC transporters;IUBMB Life;2024-08
2. Unleashing the Neurotherapeutic Potential: The Crucial Role of miR-206-3p in Facilitating Hsp90aa1-Mediated Central Nervous System Injuries During Heat Stroke;Molecular Neurobiology;2024-07-12
3. Epithelial–mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC);Cancer Pathogenesis and Therapy;2024-07
4. The Role and Therapeutic Potential of Non-coding RNAs in Resistance to EGFR-TKIs targeted therapy for Non-small Cell Lung Cancer;Current Medicinal Chemistry;2024-02-16
5. Emerging role of competing endogenous RNA in lung cancer drug resistance;Journal of Chemotherapy;2023-12-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3